Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2008-11-20 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2008
Regulatory Filings
2008-11-20 English
Regulatory Filings 2008
Regulatory Filings
2008-11-20 Danish
Regulatory Filings 2008
Regulatory Filings Classification · 98% confidence The document is titled "Selskabsmeddelelse nr. 17/2008" (Company Announcement No. 17/2008) and is issued by ALK-Abelló A/S to NASDAQ OMX Copenhagen A/S. The content announces a regulatory approval (GRAZAX® approved in Europe for treating children) and explicitly states, "Meddelelsen ændrer ikke ALKs finansielle forventninger for 2008." This structure—a brief, formal announcement of a material event directed to a stock exchange—is characteristic of a regulatory filing that is not a full financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a general, material announcement that doesn't fit the more specific categories (like DIV, DIRS, or ER), the most appropriate classification is the general regulatory filing category.
2008-11-20 English
Regulatory Filings 2008
Regulatory Filings
2008-11-12 Danish
Report Publication Announcement 2008
Report Publication Announcement Classification · 99% confidence The document is a short announcement (2202 characters) from ALK-Abelló A/S, titled 'Selskabsmeddelelse nr. 15/2008' (Company Announcement no. 15/2008). The core content states that ALK will publish its interim report for 9 months (Q3) 2008 on November 20, 2008, and will hold a conference call afterward. Since the document is an announcement about the future publication of a report (Interim Report/Q3 results) and includes details about a subsequent conference call, it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) itself. This aligns with Rule #2 (The 'MENU VS MEAL' Rule).
2008-11-12 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is titled "Selskabsmeddelelse nr. 14/2008" (Company Announcement No. 14/2008) from ALK, dated October 22, 2008, and is addressed to NASDAQ OMX Copenhagen A/S. It details new clinical results regarding their product GRAZAX®. This format—a brief, official announcement of material, non-financial news (like clinical trial updates) released via a stock exchange—is characteristic of a general regulatory filing or company announcement that doesn't fit the specific financial report categories (10-K, IR, ER, etc.). Since it is a formal announcement of significant, non-scheduled news, and it is not a transcript (CT), a management discussion (MDA), or a specific financial report, the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2008-10-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.